IL32 Antikörper

Produktnummer ABIN7670667

Der Kaninchen-Polyklonal Anti-IL32-Antikörper wurde für ELISA (Capture) validiert. Er ist geeignet zum Nachweis von IL32 in Proben aus Human. }

Kurzübersicht für IL32 Antikörper (ABIN7670667)

Target: IL32 (Interleukin 32 (IL32))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IL32 Antikörper ist unkonjugiert

Applikation: ELISA (Capture)

Produktdetails anti-IL32 Antikörper

Verwendungszweck: IL-32 Polyclonal Antibody(Capture)

Aufreinigung: Antigen Affinity Purification

Immunogen: Recombinant Human IL-32 protein expressed by E.coli

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: ELISA Capture 2-8 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: Sterile PBS , pH 7.4

Konservierungsmittel: Without preservative

Handhabung: Avoid freeze / thaw cycles. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C Valid for 1 month or -20°C Valid for 12 months

Haltbarkeit: 12 months

Details zu IL32

Target: IL32 (Interleukin 32 (IL32))

Andere Bezeichnung: IL-32

Hintergrund: Interleukin-32,IL-32,Natural killer cells protein 4,Tumor necrosis factor alpha-inducing factor,IL32,NK4,TAIF,IL-32 is a recently discovered cytokine that induces various proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines in both human and mouse cells through the NF-kappaB and p38 MAPK inflammatory signal pathways. It is regulated robustly by other major proinflammatory cytokines and is crucial to inflammation and immune responses. Four of the IL-32 isoforms (alpha, beta, gamma, and delta) are the most representative IL-32 transcripts, and the gamma isoform of IL-32 is the most active, although all isoforms are biologically active. IL-32, a cytokine produced mainly by T, natural killer, and epithelial cells induces significant amounts of TNFalpha and MIP-2 and increases the production of both cytokines in a dose-dependent manner. IL-32 has been implicated in inflammatory disorders, Mycobacterium tuberculosis infections, inflammatory bowel disease, and influenza A virus infection, as well as in some autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and in the human stomach cancer, human lung cancer, and breast cancer tissues. Thus, IL-32 expression might be valuable as a biomarker for cancer.

UniProt: P24001